Friday, March 13, 2020


How the New Coronavirus Spreads and Progresses – And Why One Test May Not Be Enough

By Nina Bai

In the weeks since the outbreak, the disease has been named COVID-19 by the World Health Organization. (The virus itself has been named SARS-CoV-2 by the International Committee on Taxonomy of Viruses).

UC San Francisco infectious disease expert Charles Chiu, MD, PhD, has been following the disease since its outbreak and provided the latest updates on what science has revealed about how the coronavirus is transmitted, what happens to someone who’s infected, and why a single diagnostic test may not be enough.

The new coronavirus is spread through droplets and surfaces.
The principal mode of transmission is still thought to be respiratory droplets, which may travel up to six feet from someone who is sneezing or coughing. The new coronavirus isn’t believed to be an airborne virus, like measles or smallpox, that can circulate through the air. “If you have an infected person in the front of the plane, for instance, and you’re in the back of the plane, your risk is close to zero simply because the area of exposure is thought to be roughly six feet from the infected person,” said Chiu.

Close contact with an infectious person, such as shaking hands, or touching a doorknob, tabletop or other surfaces touched by an infectious person, and then touching your nose, eyes, or mouth can also transmit the virus.

Chiu stresses that we do not yet have definitive data on how long the new coronavirus can survive on surfaces, but based on data from other coronaviruses such as SARS, it may be for up to two days at room temperatures.

New reports raised the possibility that the virus may be spread by fecal contamination of the environment, such as through leaky sewage pipes. Infections across multiple floors of a building due to contaminated bathroom pipes was previously demonstrated for SARS coronavirus.

It’s probably less deadly than SARS, more deadly than the flu.
The latest estimates based on the reported number of cases and deaths suggests the death rate is about 2 percent. For comparison, SARS had a death rate of about 10 percent and seasonal influenza has a death rate of 0.1 percent.

However, according to Chiu, the actual death rate of the new coronavirus very well may be lower than 2 percent because the total number of cases likely has been underreported. Not all cases are promptly identified, especially in Wuhan, where medical services are stretched thin, and there have been documented cases of asymptomatic and minimally symptomatic transmission, which are harder to identify and track.

“I believe that the actual calculated death rates will go down over time, perhaps to less than 1 percent” said Chiu.

This is how the disease progresses: (Day 7 is the worst.)
“From published reports, we do now have a better sense of the overall time course for the disease,” said Chiu. Once a person is exposed and becomes infected, the incubation period before the onset of symptoms is about five days, although this can vary from two to 11 days. Flu-like symptoms are often mild at first and some patients recover without the symptoms becoming more serious. But for a subset who get worse, day four after the onset of symptoms is usually when they seek medical care because they develop shortness of breath and early pneumonia, said Chiu, and they may become critically ill by day seven. After day 11, most patients who survive are on their way to recovery.

Treatments are still experimental and unproven.
No drugs or vaccines yet have been proven effective against the virus, but some experimental treatments are being tried. These include Remdesivir, an antiviral drug that was originally developed for Ebola, which was given to the patient in Washington State and is being given to some patients in China, said Chiu. Other groups are trying various combinations of antivirals, including anti-HIV drugs. In the absence of a proven drug therapy, patients receive supportive care, such as supplementary oxygen, fluids, and antibiotics to guard against secondary bacterial infections.

Even those who recover from COVID-19 might not be immune forever.
“Unfortunately, we don’t know yet whether or not the body’s immune response would protect you from subsequent infection,” said Chiu. It is known that exposure to the four seasonal human coronaviruses (that cause the common cold) does produce immunity to those particular viruses. In those cases, the immunity lasts longer than that of seasonal influenza, but is probably not permanent, said Chiu.

A single negative test may not rule out infection.
The currently available diagnostic test is a PCR test developed by the CDC, which looks for RNA from the virus. However, hospitalized patients infected with the new coronavirus can have test results that vary from day to day because the amount of virus produced by the body can change throughout the course of the illness, said Chiu.

Repeat testing may be necessary to determine if a suspected person has been infected or when a patient is no longer infectious. “The take home message is that a test that looks at a single time point is not sufficient to rule out infection,” said Chiu.

Evidence from the case in Washington State also suggests that the severity of the illness does not necessarily correlate with levels of the virus in the body – meaning someone can be very infectious without seeming very sick. “That’s why there’s concern that patients who are minimally symptomatic may be fueling the outbreak simply because they don’t feel sick enough to go to the hospital,” said Chiu.

Chiu’s lab, in collaboration with the startup Mammoth Biosciences, is developing a rapid diagnostic test that could more quickly and widely monitor for the disease. The new test is a color-changing test strip that uses CRISPR to detect viral RNA and can be run in 30 minutes to an hour. “We’ve been able to run this rapid test on both control samples and patient samples and it appears to be working,” said Chiu. He hopes to optimize the test so that it can be run by anyone and deployed in low-resource areas.

Health care workers are taking maximal precautions when treating COVID-19 patients.
To protect against infection by the new coronavirus, health care workers wear personal protective equipment such as gowns, gloves, face shields, and N95 respirator masks when they are in the same room as a patient who is in isolation. “All health care personnel get regular fittings of N95 masks to ensure that they are worn properly,” said Chiu. These precautions are meant to protect against contact, droplet and airborne transmission. The additional airborne precautions are taken in the health care setting because some medical procedures, such as endotracheal intubation, may cause secretions to be aerosolized. Chiu said that, per CDC recommendations, items brought into the room are preferably disposable, or if not, are disinfected before being removed from the room, and after the patient is discharged from the hospital, the entire room is disinfected.

Preparedness and Response regarding COVID-19

• To view all technical guidance documents regarding COVID-19, please go to this webpage.
• WHO is working closely with International Air Transport Association (IATA) and have jointly developed a guidance document to provide advice to cabin crew and airport workers, based on country queries. The guidance can be found on the IATA webpage.
• WHO has been in regular and direct contact with Member States where cases have been reported. WHO is also informing other countries about the situation and providing support as requested.
• WHO has developed interim guidance for laboratory diagnosis, advice on the use of masks during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak, clinical management, infection prevention and control in health care settings, home care for patients with suspected novel coronavirus, risk communication and community engagement and Global Surveillance for human infection with novel coronavirus (2019-nCoV).
• WHO is working with its networks of researchers and other experts to coordinate global work on surveillance, epidemiology, mathematical modelling, diagnostics and virology, clinical care and treatment, infection prevention and control, and risk communication. WHO has issued interim guidance for countries, which are updated regularly.
• WHO has prepared a disease commodity package that includes an essential list of biomedical equipment, medicines and supplies necessary to care for patients with 2019-nCoV.
• WHO has provided recommendations to reduce risk of transmission from animals to humans.
• WHO has published an updated advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV.
• WHO has activated the R&D blueprint to accelerate diagnostics, vaccines, and therapeutics.
• WHO has developed online courses on the following topics: A general introduction to emerging respiratory viruses, including novel coronaviruses (available in Arabic, English, French, Chinese, Spanish, Portuguese, and Russian); Critical Care of Severe Acute Respiratory Infections; and Health and safety briefing for respiratory diseases - ePROTECT (available in English and French); Infection Prevention and Control for Novel Coronavirus (COVID-19) (available in English and Russian); Critical Care Severe Acute Respiratory Infection (available in English and French); and COVID-19 Operational Planning Guidelines and COVID-19 Partners Platform to support country preparedness and response.
• WHO is providing guidance on early investigations, which are critical in an outbreak of a new virus. The data collected from the protocols can be used to refine recommendations for surveillance and case definitions, to characterize the key epidemiological transmission features of COVID-19, help understand spread, severity, spectrum of disease, impact on the community and to inform operational models for implementation of countermeasures such as case isolation, contact tracing and isolation. Several protocols are available here. One such protocol is for the investigation of early COVID-19 cases and contacts (the “First Few X (FFX) Cases andcontact investigation protocol for 2019-novel coronavirus (2019-nCoV) infection”). The protocol is designed to gain an early understanding of the key clinical, epidemiological and virological characteristics of the first cases of COVID-19 infection detected in any individual country, to inform the development and updating of public health guidance to manage cases and reduce the potential spread and impact of infection.

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_2
Q&A: Similarities and differences – COVID-19 and influenza 

As the COVID-19 outbreak continues to evolve, comparisons have been drawn to influenza. Both cause respiratory disease, yet there are important differences between the two viruses and how they spread. This has important implications for the public health measures that can be implemented to respond to each virus.

Q. How are COVID-19 and influenza viruses similar? Firstly, COVID-19 and influenza viruses have a similar disease presentation. That is, they both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death.

Secondly, both viruses are transmitted by contact, droplets and fomites. As a result, the same public health measures, such as hand hygiene and good respiratory etiquette (coughing into your elbow or into a tissue and immediately disposing of the tissue), are important actions all can take to prevent infection.

Q. How are COVID-19 and influenza viruses different? The speed of transmission is an important point of difference between the two viruses. Influenza has a shorter median incubation period (the time from infection to appearance of symptoms) and a shorter serial interval (the time between successive cases) than COVID-19 virus. The serial interval for COVID-19 virus is estimated to be 5-6 days, while for influenza virus, the serial interval is 3 days. This means that influenza can spread faster than COVID19.

Further, transmission in the first 3-5 days of illness, or potentially pre-symptomatic transmission –transmission of the virus before the appearance of symptoms – is a major driver of transmission for influenza. In contrast, while we are learning that there are people who can shed COVID-19 virus 24-48 hours prior to symptom onset, at present, this does not appear to be a major driver of transmission.

The reproductive number – the number of secondary infections generated from one infected individual – is understood to be between 2 and 2.5 for COVID-19 virus, higher than for influenza. However, estimates for both COVID-19 and influenza viruses are very context and time-specific, making direct comparisons more difficult.

Children are important drivers of influenza virus transmission in the community. For COVID-19 virus, initial data indicates that children are less affected than adults and that clinical attack rates in the 0-19 age group are low. Further preliminary data from household transmission studies in China suggest that children are infected from adults, rather than vice versa.

While the range of symptoms for the two viruses is similar, the fraction with severe disease appears to be different. For COVID-19, data to date suggest that 80% of infections are mild or asymptomatic, 15% are severe infection, requiring oxygen and 5% are critical infections, requiring ventilation. These fractions of severe and critical infection would be higher than what is observed for influenza infection.

Those most at risk for severe influenza infection are children, pregnant women, elderly, those with underlying chronic medical conditions and those who are immunosuppressed. For COVID-19, our current understanding is that older age and underlying conditions increase the risk for severe infection.

Mortality for COVID-19 appears higher than for influenza, especially seasonal influenza. While the true mortality of COVID-19 will take some time to fully understand, the data we have so far indicate that the crude mortality ratio (the number of reported deaths divided by the reported cases) is between 3-4%, the infection mortality rate (the number of reported deaths divided by the number of infections) will be lower. For seasonal influenza, mortality is usually well below 0.1%. However, mortality is to a large extent determined by access to and quality of health care. 

Q. What medical interventions are available for COVID-19 and influenza viruses? While there are a number of therapeutics currently in clinical trials in China and more than 20 vaccines in development for COVID-19, there are currently no licensed vaccines or therapeutics for COVID-19. In contrast, antivirals and vaccines available for influenza. While the influenza vaccine is not effective against COVID-19 virus, it is highly recommended to get vaccinated each year to prevent influenza infection.

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_2

How to make Hand Sanitizer


  • 2/3 cup 99% rubbing alcohol (isopropyl alcohol) or 190-proof grain alcohol
  • 1/3 cup pure aloe vera gel (buy leaves at Whole Food) preferably without additives
  • 8 to 10 drops essential oil, such as lime, lavender, clove, cinnamon, or peppermint




Notice that coronavirus has already jumped to the second most lethal on this list overall, and the outbreak is only just beginning. (source)

What’s more, in comparing coronavirus to the common seasonal flu, which itself kills tens of thousands of Americans each year, coronavirus is estimated to be 1.5–2.3 times more infectious and 10–50 times more lethal. Please take a moment to let that sink in.
The novel coronavirus that causes the disease COVID-19 has spread from the site of the original outbreak in China to affect 75 countries around the world. If effective controls aren't put into place, COIVID-19 could ultimately infect between 40% and 70% of the population worldwide in the coming year, according to Harvard T.H. Chan School of Public Health epidemiologist Marc Lipsitch
Most of those cases would be mild, and some people might show no symptoms at all. But the prospect of being infected with a new virus can be frightening. The symptoms to look out for, according to the Centers for Disease Control and Prevention (CDC), are fever, coughing and shortness of breath. These symptoms usually appear between two days and two weeks of exposure to the virus.
According to a report in the Journal of the American Medical Association, as many as 98% of COVID-19 patients have a fever, between 76% and 82% have a dry cough, and 11% to 44% report exhaustion and fatigue. 
The disease appears to become more severe with age, with the 30- to 79-year-old age range predominating the detected cases in Wuhan, where the outbreak began, according to a study in JAMA. Children seem to be at less risk of suffering noticeable symptoms of the disease. 
In more serious cases of COVID-19, patients experience pneumonia, which means their lungs begin to fill with pockets of pus or fluid. This leads to intense shortness of breath and painful coughing. 
Currently, testing for the virus that causes COVID-19 in the United States is limited to people with severe symptoms, according to Paul Biddinger, the director of the emergency preparedness research, evaluation and practice program at the Harvard T.H. Chan School of Public Health, who spoke in a university webcast March 2. This means that it isn't appropriate to be tested at the first sign of a fever or sniffle. Seeking medical care for mild illness can also potentially transmit that illness, or lead to catching new illnesses in the hospital or clinic, Biddinger added. 
If you become ill with these symptoms and live in or have traveled to an area where COVID-19 is spreading, which now includes parts of the U.S., the CDC recommends calling your doctor first rather than traveling to a clinic. Physicians work with state health departments and the CDC to determine who should be tested for the new virus. However, the CDC also recommends that people with COVI-19 or any respiratory illness monitor their symptoms carefully. Worsening shortness of breath is reason to seek medical care, particularly for older individuals or people with underlying health conditions. The CDC information page has more information on what to do if you are sick. 

Coronavirus basics

The novel coronavirus, now called SARS-CoV-2, causes the disease COVID-19. The virus was first identified in Wuhan, China, on Dec. 31, 2019. Since then, it has spread to every continent except Antarctica. The death rate appears to be higher than that of the seasonal flu, but it also varies by location as well as a person's age, underlying health conditions, among other factors. For instance, in Hubei Province, the epicenter of the outbreak, the death rate reached 2.9%, whereas it was just 0.4% in other provinces in China, according to a study published Feb. 18 in the China CDC Weekly.
Scientists aren't certain where the virus originated, though they know that coronaviruses (which also include SARS and MERS) are passed between animals and humans. Research comparing the genetic sequence of SARS-CoV-2 with a viral database suggests it originated in bats. Since no bats were sold at the seafood market in Wuhan at the disease’s epicenter, researchers suggest an intermediate animal, possibly the pangolin (an endangered mammal) is responsible for the transmission to humans. There are currently no treatments for the disease, but labs are working on various types of treatments, including a vaccine.